Why the study?
Do sulfonylureas (glibenclamide and glimepiride) inhibit I(HERG) K+ currents in neuroblastoma cells and guinea-pig ventricular myocytes?
Do sulfonylureas (glibenclamide and glimepiride) inhibit I(HERG) K+ currents in neuroblastoma cells and guinea-pig ventricular myocytes?
Answers are grounded in this paper and cite their sources.
Glibenclamide inhibits HERG potassium channels, suggesting a potential mechanism for sulfonylurea-induced QT prolongation and arrhythmias.
The human ether-a-go-go-related gene (herg) encodes a K+ current (I(HERG)) which plays a fundamental role in heart excitability and in neurons by contributing to action potential repolarization and to spike-frequency adaptation, respectively. In this paper we show that I(HERG), recorded in neuroblastoma cells and guinea-pig ventricular myocytes, was reversibly inhibited by the K(ATP) channel blocker glibenclamide (IC50 = 74 microM). The voltage and use dependence of glibenclamide blockade were also evaluated. Another sulfonylurea, glimepiride, had less effective results in blocking I(HERG). The findings of this study are relevant to the interpretation of glibenclamide effects on cellular electrophysiology and suggest that oral antidiabetic therapy with sulfonylureas may contribute to iatrogenic QT prolongation and related arrhythmias.
No takes yet. Share an insight, caveat, or question.
Rosati et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: